KPV: Clinical Guide for Prescribing Practices
KPV is a tripeptide fragment (Lys-Pro-Val) derived from the C-terminal end of alpha-melanocyte stimulating hormone (alpha-MSH). It retains the anti-inflammatory properties of alpha-MSH without its melanogenic (tanning) effects. It has been studied for inflammatory bowel conditions, skin inflammation, and systemic inflammatory states.
Also Known As
How KPV Works
KPV exerts anti-inflammatory effects by entering cells and directly inhibiting NF-kB nuclear translocation, preventing transcription of pro-inflammatory cytokines including TNF-alpha, IL-6, and IL-1beta [3]. It binds melanocortin receptors (MC1R, MC3R, MC5R) on immune cells, triggering intracellular cAMP elevation that suppresses inflammatory signaling cascades [2]. Unlike full-length alpha-MSH, the tripeptide structure lacks affinity for MC1R on melanocytes, eliminating melanogenic (skin darkening) effects while preserving potent immunomodulatory activity [4].
Clinical Evidence
Preclinical studies demonstrate that KPV significantly reduces intestinal inflammation in murine colitis models, with efficacy comparable to standard anti-inflammatory agents when delivered orally or via enema [1]. In vitro studies confirm NF-kB inhibition at nanomolar concentrations in human colonocytes and peripheral blood mononuclear cells [3]. A 2003 study in the Journal of Pharmacology and Experimental Therapeutics demonstrated anti-inflammatory activity in both acute and chronic inflammation models [3]. Human clinical trial data is limited to clinical practice reports and case series, though the mechanism is well-validated through alpha-MSH research [2].
Clinical Uses
Patient Selection and Screening
Best suited for patients with inflammatory bowel conditions (ulcerative colitis, Crohn's disease) unresponsive to or intolerant of conventional therapy [1], chronic systemic inflammation with elevated CRP or inflammatory cytokines, and inflammatory skin conditions (psoriasis, eczema). Candidates should have documented inflammatory markers for objective response monitoring. Avoid in patients with active melanoma or melanocytic neoplasms due to theoretical melanocortin pathway concerns [4], though KPV itself lacks melanogenic activity.
Dosing and Administration
Subcutaneous injection: 200 to 500 mcg daily for systemic inflammation, typically for 4 to 8 week courses [2]. Oral capsule (for GI indications): 500 mcg to 1 mg daily, often in enteric-coated formulations to target intestinal delivery [1]. Topical formulations (for skin conditions): apply to affected areas twice daily. Some protocols combine subcutaneous and oral routes for patients with both systemic and GI inflammation. Treatment response should be assessed at 4 weeks with inflammatory marker reassessment.
Route: Subcutaneous injection, oral capsule, topical
Protocol notes: Administered via subcutaneous injection, oral capsule, or topical formulation depending on clinical indication. Gut-targeted protocols often use oral or rectal administration.
Side Effects and Monitoring
Clinical Considerations
Practice Economics
KPV fills a high-demand niche in practices treating chronic inflammatory and GI conditions, where patients have often exhausted conventional options and are seeking peptide-based alternatives [1]. The multiple route options (injection, oral, topical) allow flexible program design and tiered pricing. Practices specializing in gut health and functional gastroenterology report strong patient retention with KPV protocols, as treatment courses are typically 2 to 3 months with objective marker-based follow-up driving continued engagement.
FDA Category Status
Compounding eligibility varies; verify current FDA status before prescribing
FDA bulk drug substance category determines compounding eligibility. Category designations are subject to change; always verify the current status before prescribing. This information is provided for clinical reference and does not constitute legal or regulatory advice.
Pharmacy Integrations
Prescribe KPV through Karpa's integrated compounding pharmacy network with one-click ordering and direct-to-patient fulfillment.
Frequently Asked Questions
How does KPV differ from other anti-inflammatory peptides like BPC-157?
What is the evidence for KPV in gut inflammation?
References
- Kannengiesser K, et al. Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease. Inflamm Bowel Dis. 2008;14(3):324-331.
- Brzoska T, et al. Alpha-melanocyte-stimulating hormone and related tripeptides: biochemistry, antiinflammatory and protective effects. Endocr Rev. 2008;29(5):581-602.
- Getting SJ, et al. KPV alpha-MSH(11-13) inhibits NF-kappaB signaling. J Pharmacol Exp Ther. 2003;306(2):631-637.
- Luger TA, et al. New insights into the functions of alpha-MSH and related peptides in the immune system. Ann N Y Acad Sci. 2003;994:133-140.
Related Peptides in Immune Support
Disclaimer: This information is intended for licensed healthcare providers only and does not constitute medical, legal, or regulatory advice. Clinical decisions should be based on your professional judgment, current evidence, and applicable state and federal regulations. Always verify FDA category status and compounding eligibility before prescribing. Content is reviewed periodically but may not reflect the most recent regulatory changes.
Prescribe KPV Through Karpa
Streamline your peptide prescribing workflow with integrated pharmacy ordering, patient tracking, and compliance documentation.
Prescribe KPV Through Karpa